Compare CLAR & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLAR | CRDF |
|---|---|---|
| Founded | 1957 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.9M | 86.8M |
| IPO Year | 1998 | 2012 |
| Metric | CLAR | CRDF |
|---|---|---|
| Price | $3.66 | $1.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $4.08 | ★ $9.63 |
| AVG Volume (30 Days) | 134.6K | ★ 699.6K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.80% | N/A |
| EPS Growth | 11.68 | ★ 27.37 |
| EPS | ★ 0.04 | N/A |
| Revenue | $228,000.00 | ★ $365,993.00 |
| Revenue This Year | $5.27 | N/A |
| Revenue Next Year | $3.99 | N/A |
| P/E Ratio | $93.00 | ★ N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $2.53 | $0.76 |
| 52 Week High | $4.03 | $3.31 |
| Indicator | CLAR | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 53.15 | 54.44 |
| Support Level | $3.52 | $0.87 |
| Resistance Level | $3.71 | $1.13 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 33.33 | 77.83 |
Clarus Corp is a designer, developer, manufacturer, and distributor of outdoor equipment and lifestyle products focused on the climb, ski, mountain, sport, and skincare markets. The company operates through the Outdoor segment, which includes Black Diamond Equipment and PIEPS, is a world-wide leader in designing, manufacturing, and marketing outdoor engineered equipment and apparel for climbing, mountaineering, trail running, backpacking, skiing, and a wide range of other year-round outdoor recreation activities. The Adventure segment, which includes Rhino-Rack, MAXTRAX and TRED, is a manufacturer of engineered automotive roof racks, trays, mounting systems, luggage boxes, carriers, recovery boards and accessories in Australia and New Zealand and U.S.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.